טבע מדווחת על תוצאות מעודדות בניסוי ומתקדמת עם הנוגדן לטיפול במחלת העור ויטיליגו

הערכה

Teva's positive trial results for its vitiligo antibody TEV-408 mark a potential breakthrough in a skin condition with limited treatment options. Half of patients reporting significant repigmentation is a strong efficacy signal, but the company's next steps in clinical development will determine whether this optimism translates into a viable therapy. The market and medical community will watch for further trial phases and eventual regulatory filings.